(Q37779240)

23 August 2017

1 reference

title

Making the best of PARP inhibitors in ovarian cancer (English)

1 reference

23 August 2017

1 reference

3

Alan Ashworth

1 reference

23 August 2017

1

Susana Banerjee

1 reference

23 August 2017

Stan B Kaye

2

1 reference

23 August 2017

language of work or name

English

0 references

publication date

10 August 2010

1 reference

Nature Reviews Clinical Oncology

23 August 2017

published in

1 reference

23 August 2017

volume

7

1 reference

23 August 2017

issue

9

1 reference

23 August 2017

page(s)

508-519

1 reference

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

21 January 2018

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Low-grade serous ovarian cancer: a unique disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Endometrioid epithelial ovarian cancer : 20 years of prospectively collected data from a single center.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Breast and ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

BRCA1 and BRCA2 as ovarian cancer susceptibility genes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

CpG Island Methylation of DNA Damage Response Genes in Advanced Ovarian Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Is It Time to Stratify for BRCA Mutation Status in Therapeutic Trials in Ovarian Cancer?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Clinical and Pathological Features of Ovarian Cancer in Women with Germ-Line Mutations ofBRCA1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Clinicopathologic features of BRCA-linked and sporadic ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Improved survival in women with BRCA-associated ovarian carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

“BRCAness” Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated WithBRCA1andBRCA2Mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Exploiting the DNA Repair Defect in BRCA Mutant Cells in the Design of New Therapeutic Strategies for Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Genome maintenance mechanisms for preventing cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Homologous recombination and non-homologous end-joining pathways of DNA double-strand break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Pathways of DNA double-strand break repair during the mammalian cell cycle

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Genetic steps of mammalian homologous repair with distinct mutagenic consequences

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Chromosomal translocation mechanisms at intronic alu elements in mammalian cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Involvement of Brca2 in DNA repair

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Brca2 (XRCC11) deficiency results in radioresistant DNA synthesis and a higher frequency of spontaneous deletions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

The concept of synthetic lethality in the context of anticancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Nicotinamide mononucleotide activation of a new DNA-dependent polyadenylic acid synthesizing nuclear enzyme

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

In silico characterization of the family of PARP-like poly(ADP-ribosyl)transferases (pARTs)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Poly(ADP-ribose) polymerase (PARP-1) is not involved in DNA double-strand break recovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

DNA recombination: the replication connection.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Brca1 controls homology-directed DNA repair

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

BRCA2 is required for homology-directed repair of chromosomal breaks

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Hallmarks of 'BRCAness' in sporadic cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Resistance to therapy caused by intragenic deletion in BRCA2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Pharmacological inhibition of poly(ADP-ribose) polymerase inhibits angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

PARP-1 inhibition prevents oxidative and nitrosative stress-induced endothelial cell death via transactivation of the VEGF receptor 2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

PARP-1 inhibition-induced activation of PI-3-kinase-Akt pathway promotes resistance to taxol.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.116

Inhibition of angiogenesis by the poly(ADP-ribose) polymerase inhibitor PJ-34.

31 March 2020

1 reference

12 December 2020

Effect of BRCA Mutations on the Length of Survival in Epithelial Ovarian Tumors

1 reference

12 December 2020

Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition

1 reference

12 December 2020

2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).

1 reference

12 December 2020

Genetics of natural populations; recombination and variability in populations of Drosophila pseudoobscura.

1 reference

12 December 2020

Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers

1 reference

12 December 2020

Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy

1 reference

12 December 2020

Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines.

1 reference

12 December 2020

10.1038/NRCLINONC.2010.116

Identifiers

DOI

1 reference

23 August 2017

1 reference